The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...

Jeff George, chairman of Lykos’ board of directors, in a statement said that Emerson’s contributions to the biotech and to the mental health field more broadly “cannot be overstated,” noting that her ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, and appointments, here’s a quick look at which stocks will be in focus in today ...

Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(IN BRIEF) GSK will present significant research at the 2024 European Respiratory Society (ERS) Congress, including data from phase III trials of its new biologic, depemokimab, for severe asthma. The ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...

Across a decade, it’s almost trebled, leaving underwhelming peer GSK in the dust. I find this impressive considering the company isn’t playing in the high-growth GLP-1 weight-loss sandbox (at ...

AstraZeneca (LSE: AZN) is a UK stock on fine form. It recently notched a 52-week high of 13,290p not long after the ...